Author

M. Craig

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Approach:statistical model· 6 Research Focus:drug response / drug discovery· 4 Research Focus:host-pathogen & immune response· 2 Approach:mechanistic / dynamical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. L. Jenner· 4 shared T. Cassidy· 2 shared A. M. Smith· 1 shared A. P. Smith· 1 shared A. R. A. Anderson· 1 shared A. Surendran· 1 shared C. Burlot· 1 shared C. L. Davis· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. L. Jenner

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Insights into B Cell and Antibody Kinetics Against SARS-CoV-2 Variants Using Mathematical Modelling

S. Farhang-Sardroodi, X. Deng, S. Portet, J. Arino, M. Craig

This study uses mathematical modeling to analyze B cell and antibody dynamics against SARS-CoV-2 variants, showing reduced neutralization against Omicron and enhanced secondary response.

bioRxiv · Nov 10, 2023 · PreprintImmunology

Deconstructing the contributions of heterogeneity to combination treatment of hormone sensitive breast cancer

S. Linn, J. Moore-Ott, R. Shuttleworth, W. Zhang, M. Craig, A. L. Jenner

The paper develops a mathematical model to study how tumor heterogeneity affects the response to combination therapy in hormone receptor-positive breast cancer, finding that pharmacokinetics and pharmacodynamics of fulvestrant drive treatment outcomes.

bioRxiv · May 19, 2023 · PreprintCancer Biology

Approaches to generating virtual patient cohorts with applications in oncology

A. Surendran, J. L. Sauteur-Robitaille, D. Kleimeier, J. L. Gevertz, K. P. Wilkie, A. L. Jenner, M. Craig

This paper discusses methods for generating virtual patient cohorts in oncology to predict treatment responses and capture inter-individual variability.

bioRxiv · May 24, 2022 · PreprintCancer Biology

Establishing combination PAC-1 and TRAIL regimens for treating ovarian cancer based on patient-specific pharmacokinetic profiles using in silico clinical trials

O. Cardinal, C. Burlot, Y. Fu, P. Crosley, M. Hitt, M. Craig, A. L. Jenner

This paper uses in silico clinical trials to optimize combination PAC-1 and TRAIL therapy for ovarian cancer based on patient-specific pharmacokinetic profiles, identifying optimal treatment schedules and patient subgroups.

bioRxiv · Mar 29, 2022Cancer Biology

The role of memory in non-genetic inheritance and its impact on cancer treatment resistance

T. Cassidy, D. Nichol, M. Robertson-Tessi, M. Craig, A. R. A. Anderson

This paper develops a mathematical model of stochastic phenotype switching in cancer cells to show how non-genetic inheritance contributes to treatment resistance and proposes a therapeutic strategy to enhance treatment efficacy.

bioRxiv · Feb 22, 2021Cancer Biology

COVID-19 virtual patient cohort reveals immune mechanisms driving disease outcomes

A. L. Jenner, R. A. Aogo, S. Alfonso, V. Crowe, A. P. Smith, P. A. Morel, C. L. Davis, A. M. Smith, M. Craig

The paper develops a computational model of COVID-19 immunopathology to identify immune mechanisms driving severe disease outcomes.

bioRxiv · Jan 5, 2021Immunology

Optimal Individualized Combination Immunotherapy/Oncolytic Virotherapy Determined Through In Silico Clinical Trials Improves Late Stage Melanoma Patient Outcomes

T. Cassidy, M. Craig

This study uses in silico clinical trials to optimize combination immunotherapy and oncolytic virotherapy for late-stage melanoma, showing improved patient outcomes.

bioRxiv · Mar 22, 2019Cancer Biology

Novel cytokine interactions identified during perturbed hematopoiesis

M. S. Krieger, J. M. Moreau, H. Zhang, M. Chien, J. L. Zehnder, M. A. Nowak, M. Craig

The paper identifies 61 previously unreported cytokine relationships using convergent cross-mapping in a patient with cyclic thrombocytopenia.

bioRxiv · Dec 22, 2018 · PreprintImmunology